Odesivimab Biosimilar - Research Grade

Human

Zaire Ebola virus

>1mg/ml

IgG1 - kappa

CHO Cells

Atoltivimab Biosimilar - Research Grade (ICH5362), Cosfroviximab Biosimilar - Research Grade (ICH5450), Larcaviximab Biosimilar - Research Grade (ICH5627), Maftivimab Biosimilar - Research Grade (ICH5666), Porgaviximab Biosimilar - Research Grade (ICH5780)

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

The Zaire ebolavirus glycoprotein is a defining antigen in filovirus neutralization and antiviral research. This recombinant human IgG1 kappa antibody is an unconjugated, non-therapeutic analog of odesivimab, expressed in CHO cells against Zaire Ebola virus. Released strictly for research use only, it is formulated to low endotoxin for in vivo compatibility and manufactured in scalable milligram (mg) to gram (g) quantities to meet high-throughput laboratory demand. It functions as a defined reagent for neutralization assays, viral-entry studies, functional characterization, and preclinical filovirus models. Reliable batch-to-batch consistency suits laboratories running extended experimental campaigns.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Odesivimab biosimilar available in bulk or gram quantities?

A: Yes — the Odesivimab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is research-grade Odesivimab suitable for in vivo studies?

A: Yes, it is supplied as a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Odesivimab biosimilar target?

A: It is an unconjugated, non-therapeutic biosimilar monoclonal antibody analogous to Odesivimab that binds Zaire Ebola virus; for research use only (RUO).